Vivos Therapeutics (VVOS) Intangibles (2019 - 2026)

Vivos Therapeutics (VVOS) has reported Intangibles for 8 consecutive years, with $3.6 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Intangibles rose 63.51% year-over-year to $3.6 million in Q2 2026; TTM through Jun 2026 was $3.6 million, a 63.51% increase from a year earlier, with the FY2025 full-year figure at $4.0 million, up 889.0% from the prior year.
• Intangibles was $3.6 million for Q2 2026 at Vivos Therapeutics, down from $3.8 million in the prior quarter.
• Over five years, Intangibles peaked at $4.0 million in Q4 2025 and troughed at $302000.0 in Q4 2022.
• A 5-year average of $1.2 million and a median of $414500.0 in 2023 frame the typical range for Intangibles.
• Across the five-year window, Intangibles tumbled 87.22% in 2022 and jumped 972.35% in 2026, its largest moves.
• Over 5 years, Intangibles stood at $302000.0 in 2022, then surged by 39.07% to $420000.0 in 2023, then slipped by 2.62% to $409000.0 in 2024, then surged by 889.0% to $4.0 million in 2025, then decreased by 10.06% to $3.6 million in 2026.
• The last three Intangibles figures came in at $3.6 million (Q2 2026), $3.8 million (Q1 2026), and $4.0 million (Q4 2025), per Business Quant data.